Sidebar

Our current research includes three arching themes:

 

I. Deterministic cell therapies enabled by iPS cells and CRISPR nucleases.

1. Engineered iPS cell-based therapies.

 

II. Genome wide modulation of human cell systems enabled by CRISPR nucleases.

1. Creation of cell therapies enabled by CRISPR nucleases and iPS cells (P-PAD-22-76) funded by RCL.

 

III. Gain of function cell therapies enabled by iPS cells and CRISPR nucleases.

1. CRISPR-Cas9 enabled cell-based therapeutics.

2. Advanced Nuclease-enabled Regenerative Medicine Therapies against cancer (NRMT - P-MIP-23-1) funded by RCL.

 

Group of Targeted Delivery of CRISPR-Cas System and Cell/Immunotherapies

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies. More information